A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression
- J Clin Invest. 2023 Nov 15;133(22):e163802. doi: 10.1172/JCI163802.
- 1. Department of Oncological Sciences, The Tisch Cancer Institute, Mount Sinai Icahn School of Medicine, New York, New York, USA.
- 2. Department of Pediatrics, AFLAC Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Winship Cancer Institute, and.
- 3. Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
- 4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- 5. Department of Neurology, Rutgers University, New Brunswick, New Jersey, USA.
- 6. Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- 7. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- 8. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- 9. Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA.
- 10. Emory University Department of Microbiology and Immunology, Emory Vaccine Center, Atlanta, Georgia, USA.
- 11. Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- 12. Department of Neurosurgery and.
- 13. Department of Pathology and Molecular and Cell-Based Medicine, Mount Sinai Icahn School of Medicine, New York, New York, USA.
- 14. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- 15. The Ludwig Center at Harvard, Boston, Massachusetts, USA.
- 16. The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- 17. Lowance Center for Human Immunology and Emory Vaccine Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- 18. Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Monocytes and monocyte-derived macrophages (MDMs) from blood circulation infiltrate glioblastoma (GBM) and promote growth. Here, we show that PDGFB-driven GBM cells induce the expression of the potent proinflammatory cytokine IL-1β in MDM, which engages IL-1R1 in tumor cells, activates the NF-κB pathway, and subsequently leads to induction of monocyte chemoattractant proteins (MCPs). Thus, a feedforward paracrine circuit of IL-1β/IL-1R1 between tumors and MDM creates an interdependence driving PDGFB-driven GBM progression. Genetic loss or locally antagonizing IL-1β/IL-1R1 leads to reduced MDM infiltration, diminished tumor growth, and reduced exhausted CD8+ T cells and thereby extends the survival of tumor-bearing mice. In contrast to IL-1β, IL-1α exhibits antitumor effects. Genetic deletion of Il1a/b is associated with decreased recruitment of lymphoid cells and loss-of-interferon signaling in various immune populations and subsets of malignant cells and is associated with decreased survival time of PDGFB-driven tumor-bearing mice. In contrast to PDGFB-driven GBM, Nf1-silenced tumors have a constitutively active NF-κB pathway, which drives the expression of MCPs to recruit monocytes into tumors. These results indicate local antagonism of IL-1β could be considered as an effective therapy specifically for proneural GBM.
-
Cat. No.Product NameDescriptionTargetResearch Area
-